17-Jun-2022

Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market is predicted to increase at a high 7% CAGR over the forecast period 2022-2030

The Gaucher and Pompe Disease ERT Market is anticipated to record a positive growth trajectory, despite facing a glitch in the initial months of COVID-19, due to rising orphan drug status designation to several drug candidates by the FDA. The market is further growing due to surge in number of partnerships and collaborations among key market players.

Key Highlights

Europe to remain lucrative in the market, recording majority of the revenue share.
The type-1 Gaucher disease segment will record a significant growth pace amid the forecast period.
Parenteral administration remain highly preferred over oral route of administration.
Online pharmacies are likely to gain traction, growing at around 7% of CAGR during 2022-2030.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771

Drivers

Rising incidences of lysosomal storage disorders (LSD), across the globe is driving the market growth.
Thriving orphan drug designations is anticipated to broaden the market scope over the assessment period.
Increasing prevalence of genetic disorders all over the world has boosted the growth in the market.

Restraints

Alternative treatment approaches for more efficient treatment is anticipated to hamper the market growth.
Presence of the pathological and blood-brain barrier preconditions further prove to be hindrances for efficient adoption of ERT.

Key Segments of Gaucher and Pompe Diseases ERT Industry Survey

Gaucher and Pompe Diseases ERT Market by Therapeutic Condition:

Gaucher Disease
- Type 1 (Non-neuropathic)
- Type 2 (Acute Infantile Neuronopathic)
- Type 3 Gaucher Disease (Chronic Neuronopathic)
- Perinatal Lethal Gaucher Disease
- Cardiovascular Gaucher Disease
Pompe Disease
- Classic Infantile-onset
- Non-classic Infantile-onset
- Late-onset

Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-12771

Gaucher and Pompe Diseases ERT Market by Route of Administration:

Oral
Parenteral

Gaucher and Pompe Diseases ERT Market by Distribution Channel:

Hospital Pharmacies
Specialty Treatment Pharmacies
Retail Pharmacies
Online Pharmacies

Gaucher and Pompe Diseases ERT Market by Region:

North America Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Latin America Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Europe Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
East Asia Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
South Asia & Pacific Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Middle East & Africa (MEA) Gaucher and Pompe Diseases Enzyme Replacement Therapy Market

COVID-19 Impact on the Market

COVID-19 has severely impacted the worldwide healthcare sector. Regarding treatments and surgeries, key priority is inclining towards COVID-19 positive tested patients, bringing about postponement and delays of some procedures. This has further affected the Gaucher & Pompe Disease ERT market, registering a shortfall for hospital-based treatment. However, the slowdown didnt lasted for long, as government authorities leading healthcare providers to continue treatment for Type-3 and Type-1 Gaucher Disease patients.

Competitive Landscape

The Gaucher & Pompe Disease ERT market is characterised by the existence of a number of prominent pharmaceutical and healthcare corporations, focusing on path breaking technological advancements to present more efficient therapeutic solutions on account of strategic collaborations with several entities.

Key players identified in the market are Pfizer Inc., Tadeka Pharmaceuticals, BioMarin Pharmaceutical Inc., Merck KGaA Alexion Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Sanofi SA, Ultragenyx Pharmaceutical Inc., Shire PLC,AbbVie Inc., and Sigma-Tau Pharmaceuticals Inc.

Key Segments of Gaucher and Pompe Diseases ERT Industry Survey

Gaucher and Pompe Diseases ERT Market by Therapeutic Condition:

Gaucher Disease
- Type 1 (Non-neuropathic)
- Type 2 (Acute Infantile Neuronopathic)
- Type 3 Gaucher Disease (Chronic Neuronopathic)
- Perinatal Lethal Gaucher Disease
- Cardiovascular Gaucher Disease
Pompe Disease
- Classic Infantile-onset
- Non-classic Infantile-onset
- Late-onset

Gaucher and Pompe Diseases ERT Market by Route of Administration:

Oral
Parenteral

Gaucher and Pompe Diseases ERT Market by Distribution Channel:

Hospital Pharmacies
Specialty Treatment Pharmacies
Retail Pharmacies
Online Pharmacies

Gaucher and Pompe Diseases ERT Market by Region:

North America Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Latin America Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Europe Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
East Asia Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
South Asia & Pacific Gaucher and Pompe Diseases Enzyme Replacement Therapy Market
Middle East & Africa (MEA) Gaucher and Pompe Diseases Enzyme Replacement Therapy Market

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Editor Details

Company:
- MARKITWIRED
Website:
- MARKITWIRED

Last Updated: 17-Jun-2022